Daily Anesthesiology Research Analysis
Three impactful anesthesiology-adjacent studies stood out: a mechanistic BJA report showing propofol directly suppresses presynaptic norepinephrine release in the locus coeruleus, an external European validation of a deep-learning ECG model (PreOpNet) for 30-day perioperative risk, and a large ELSO registry analysis linking left ventricular venting during VA-ECMO to higher odds of acute brain injury without mortality benefit. Together, they advance mechanistic understanding, refine risk stratifi
Summary
Three impactful anesthesiology-adjacent studies stood out: a mechanistic BJA report showing propofol directly suppresses presynaptic norepinephrine release in the locus coeruleus, an external European validation of a deep-learning ECG model (PreOpNet) for 30-day perioperative risk, and a large ELSO registry analysis linking left ventricular venting during VA-ECMO to higher odds of acute brain injury without mortality benefit. Together, they advance mechanistic understanding, refine risk stratification, and inform critical care practice.
Research Themes
- Anesthetic mechanisms within the locus coeruleus–noradrenergic system
- AI-enabled perioperative risk stratification using ECG and biomarkers
- ECMO management strategies and neurologic complications
Selected Articles
1. Propofol inhibits norepinephrine release in vivo at presynaptic varicosities of locus coeruleus neurones in zebrafish larvae.
Using in vivo electrophysiology, chemogenetics, and imaging in zebrafish larvae, the authors show that propofol directly suppresses norepinephrine release at presynaptic varicosities of locus coeruleus neurons. This establishes a presynaptic noradrenergic mechanism contributing to anesthetic-induced hypnosis beyond effects on excitability and synaptic input.
Impact: This work reveals a previously unproven presynaptic site of action for propofol in the LC–NE system, advancing mechanistic understanding of anesthesia.
Clinical Implications: While preclinical, these findings support targeting the LC–NE axis for sedative design and may explain arousal, hemodynamic, and delirium-related effects of agents that modulate noradrenergic tone.
Key Findings
- Propofol directly inhibits norepinephrine release at presynaptic varicosities of LC–NE neurons in vivo.
- The study leveraged in vivo whole-cell recordings, chemogenetics, and time-lapse imaging in intact zebrafish larvae.
- Findings establish a presynaptic noradrenergic mechanism contributing to anesthetic-induced hypnosis.
Methodological Strengths
- In vivo mechanistic interrogation combining electrophysiology, chemogenetics, and optical imaging
- Cellular-resolution assessment at individual presynaptic varicosities
Limitations
- Findings are in zebrafish larvae with uncertain translatability to humans
- Incomplete mechanistic delineation in the abstract (e.g., calcium dynamics, receptor targets) and no human validation
Future Directions: Validate presynaptic noradrenergic suppression across species, quantify dose–effect relationships relevant to clinical sedation, and identify molecular mediators for targeted drug development.
BACKGROUND: Understanding the mechanisms by which general anaesthetics induce loss of consciousness remains one of the important scientific challenges in medicine and neuroscience. The locus coeruleus-norepinephrine (LC-NE) system plays important roles in general anaesthesia. Both i.v. and inhalation anaesthetics can reduce NE signalling by suppressing the excitatory synaptic inputs and intrinsic excitability of LC-NE neurones. However, it remains unknown whether anaesthetics can directly target presynaptic sites on LC-NE neurone axons to impair NE release. METHODS: In vivo whole-cell recording and chemogenetics were used to control the activity of LC-NE neurones in intact larval zebrafish, while in vivo time-lapse imaging was used to examine NE release and Ca RESULTS: Propofol directly inhibited NE release from individual presynaptic varicosities of LC-NE neurones, because GRAB CONCLUSIONS: Propofol can directly target the locus coeruleus norepinephrine neurone axons to suppress norepinephrine release at presynaptic varicosities.
2. External validation of PreOpNet to predict 30-day mortality after major non-cardiac surgery using digital electrocardiogram.
In 6,098 high-risk European patients undergoing major non-cardiac surgery, PreOpNet showed moderate discrimination for 30-day death (AUC 0.707) and MACE (0.675), overestimated risk, and outperformed RCRI for death but not MACE. High-sensitivity troponin T remained superior, yet combining PreOpNet with RCRI and/or hs-cTnT added prognostic value.
Impact: This is a large, prospective external validation in the guideline-relevant high-risk cohort, clarifying where a deep-learning ECG model adds value in perioperative risk assessment.
Clinical Implications: PreOpNet should not replace current tools but may be integrated with RCRI and hs-cTnT to refine 30-day risk stratification and triage for perioperative monitoring and optimization.
Key Findings
- PreOpNet discrimination: AUC 0.707 for death and 0.675 for MACE; calibration showed risk overestimation.
- Outperformed RCRI for death prediction (AUC 0.644) but not for MACE (RCRI 0.662).
- Hs-cTnT was superior (AUC 0.762 for death, 0.743 for MACE); combining PreOpNet with RCRI and/or hs-cTnT improved prognostication.
Methodological Strengths
- Prospective, multicenter European cohort of high-risk surgical patients
- Direct comparison with RCRI and hs-cTnT and assessment of incremental value
Limitations
- Overestimation indicates calibration issues requiring recalibration for deployment
- Generalizability may be limited to European high-risk populations; black-box model interpretability remains limited
Future Directions: Recalibrate and prospectively test integrated pathways (PreOpNet + hs-cTnT + RCRI) to guide monitoring and interventions; explore explainable AI to enhance trust and adoption.
PreOpNet is a novel deep-learning algorithm using 12-lead digital electrocardiogram (ECG) for preoperative risk assessment of all-cause death and major adverse cardiac events (MACE) within 30 days. Its performance in European high-risk patients undergoing major non-cardiac surgery-the target population for guideline-recommended risk assessment-and comparison to high-sensitivity cardiac troponin T (hs-cTnT), is unknown. In a prospective European study (2014-2019), 6098 high-risk patients with available ECGs were enrolled. PreOpNet showed moderate discrimination for death (AUC 0.707) and MACE (0.675), but overestimated risk. It outperformed the revised cardiac risk index (RCRI) for death (AUC 0.644), but not for MACE (0.662). Hs-cTnT remained superior for both outcomes (AUC 0.762 and 0.743). Importantly, PreOpNet provided incremental prognostic value when combined with RCRI and/or hs-cTnT. PreOpNet has limited benefit for preoperative risk stratification in high-risk surgical patients as a stand-alone test. However, it holds promise when used in conjunction with RCRI and hs-cTnT. Clinical Trial Registration: ClinicalTrials.gov number: NCT02573532; https://www.clinicaltrials.gov/study/NCT02573532 .
3. Impact of Left Ventricular Venting on Acute Brain Injury in Patients With Cardiogenic Shock: An Extracorporeal Life Support Organization Registry Analysis.
In 13,276 VA-ECMO patients with cardiogenic shock, LV venting was associated with higher odds of acute brain injury (aOR 1.67) but no mortality difference versus no venting. Among matched cohorts, ABI and mortality risks did not differ between intra-aortic balloon pump and microaxial flow pump strategies.
Impact: This large registry analysis identifies a neurologic safety signal for LV venting during VA-ECMO, informing risk–benefit discussions and monitoring strategies without favoring one venting modality over another.
Clinical Implications: When LV venting is used on VA-ECMO, intensify neurologic monitoring and mitigation (e.g., oxygenation optimization, anticoagulation stewardship). Device choice (IABP vs microaxial pump) may be guided by other factors, as ABI and mortality risks were similar.
Key Findings
- LV venting during VA-ECMO increased odds of acute brain injury (aOR 1.67; 95% CI 1.22–2.26) versus no venting.
- No difference in hospital mortality with LV venting (aOR 1.07; 95% CI 0.90–1.27).
- No significant differences in ABI or mortality between IABP and microaxial flow pump after propensity matching.
Methodological Strengths
- Very large multicenter registry with multivariable adjustment
- Propensity score matching for device comparison (IABP vs microaxial pump)
Limitations
- Observational design with potential residual confounding and selection bias
- Limited granularity on timing, indications, and anticoagulation/neuro-monitoring protocols
Future Directions: Prospective studies to define which patients benefit from venting, optimize anticoagulation and neuroprotection, and evaluate standardized monitoring pathways to reduce ABI.
OBJECTIVES: While left ventricular (LV) venting reduces LV distension in cardiogenic shock patients on venoarterial extracorporeal membrane oxygenation (ECMO), it may also amplify risk of acute brain injury (ABI). We investigated the hypothesis that LV venting is associated with increased risk of ABI. We also compared ABI risk of the two most common LV venting strategies, percutaneous microaxial flow pump (mAFP) and intra-aortic balloon pump (IABP). DESIGN: Retrospective observational cohort study. SETTING: The Extracorporeal Life Support Organization registry. PATIENTS: Adult patients on peripheral venoarterial ECMO for cardiogenic shock (2013-2024). INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: ABI was defined as hypoxic-ischemic brain injury, ischemic stroke, or intracranial hemorrhage. Secondary outcome was hospital mortality. We compared no LV venting with: 1) LV venting, 2) mAFP, and 3) IABP using multivariable logistic regression. To compare ABI risk of mAFP vs. IABP, propensity-score matching was performed. Of 13,276 patients (median age = 58.2, 69.9% male), 1,456 (11.0%) received LV venting (65.5% mAFP and 29.9% IABP), and 525 (4.0%) had ABI. After multivariable regression, LV-vented patients had increased odds of ABI (adjusted odds ratio [aOR], 1.67; 95% CI, 1.22-2.26; p = 0.001) but no difference in mortality (aOR, 1.07; 95% CI, 0.90-1.27; p = 0.45) compared with non-LV-vented patients. In the propensity-matched cohort of IABP ( n = 231) vs. mAFP ( n = 231) patients, there was no significant difference in odds of ABI (aOR, 1.35; 95% CI, 0.69-2.71; p = 0.39) or mortality (aOR, 0.88; 95% CI, 0.58-1.31; p = 0.52). CONCLUSIONS: LV venting was associated with increased odds of ABI but not mortality in patients receiving peripheral venoarterial ECMO for cardiogenic shock. There was no difference in odds of ABI or mortality for IABP vs. mAFP patients.